OptimizeRx (OPRX) to Release Quarterly Earnings on Monday

OptimizeRx (NASDAQ:OPRX - Get Free Report) is expected to be issuing its Q1 2025 quarterly earnings data after the market closes on Monday, May 12th. Analysts expect OptimizeRx to post earnings of ($0.11) per share and revenue of $18.69 million for the quarter.

OptimizeRx Stock Performance

Shares of OPRX traded up $0.15 during trading hours on Wednesday, reaching $9.48. 96,633 shares of the company traded hands, compared to its average volume of 268,231. The stock has a market cap of $175.31 million, a P/E ratio of -7.13 and a beta of 1.28. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. The stock's fifty day moving average is $7.95 and its 200 day moving average is $6.25. OptimizeRx has a 1-year low of $3.78 and a 1-year high of $14.13.

Analysts Set New Price Targets

A number of equities research analysts recently commented on OPRX shares. B. Riley upgraded OptimizeRx to a "strong-buy" rating in a report on Wednesday, March 12th. Royal Bank of Canada reiterated a "sector perform" rating and set a $6.00 target price (down from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Finally, JMP Securities restated a "market outperform" rating and set a $8.00 target price on shares of OptimizeRx in a research report on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $9.06.

Insiders Place Their Bets

In other OptimizeRx news, Director James Paul Lang bought 321,408 shares of the business's stock in a transaction that occurred on Friday, March 14th. The stock was bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the transaction, the director now owns 389,452 shares of the company's stock, valued at $2,959,835.20. This represents a 472.35 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 6.10% of the company's stock.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.